July is Sarcoma Awareness Month
Johns Hopkins Pavilion III at Green Spring Station
The Johns Hopkins Kimmel Cancer Center’s Medical Oncology practice at Green Spring Station in Lutherville, Maryland, opened its doors in a brand new, spacious facility on June 3, 2019. Located on the first floor of Pavilion III, the practice features programs in breast cancer, lymphoma, lung cancer, melanoma, ovarian cancer, gastrointestinal cancers and genitourinary cancers.
With private exam rooms, modern infusion bays, imaging, pharmacy and lab services, the practice is designed to provide an optimal cancer care patient experience. The practice is directed by Dr. William Sharfman who holds The Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research. His areas of clinical expertise include cutaneous oncology, dermatology, gastrointestinal cancers and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of the cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program.
Sandra Bailey serves as the manager for the Johns Hopkins Kimmel Cancer Center’s Medical Oncology practice at Green Spring Station.Address
10803 Falls Road, Suite 1500
Lutherville-Timonium, MD 21093
The Spinal Tumor Multidisciplinary Program
With multiple specialists, personalized treatment and patient & caregiver support, the Spinal Tumor Multidisciplinary Program provides comprehensive care to patients with primary and metastatic spine cancers.
Johns Hopkins Research Focused on Early Stage Bladder Cancer Wins $3.2 Million Federal Grant
Researchers from the Johns Hopkins Kimmel Cancer Center’s Greenberg Bladder Cancer Institute and Bloomberg~Kimmel Institute for Cancer Immunotherapy in collaboration with the Brady Urological Institute, and the Center for Computational Genomics at Johns Hopkins earned a $3.2 million grant from the National Institutes of Health to study new treatments for early-stage bladder cancer. The new study called ADAPT-BLADDER, is aimed at better treatments for cancer recurrence and is the first to explore a combination of immunotherapy, standard treatment and radiation therapy. “Studying the benefits of immunotherapy drugs in high-risk non-muscle invasive bladder cancer patients that have relapsed disease after standard BCG therapy is a natural next step, says principal investigator Noah Hahn, M.D., deputy director of the Greenberg Bladder Cancer Institute. “If this trial is successful, it could change the care of non-muscle invasive bladder cancer to a multidisciplinary treatment model.”